These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 38615277)
21. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis. Morgan A; Tallantyre E; Ontaneda D Expert Rev Neurother; 2023 May; 23(5):433-444. PubMed ID: 37129299 [TBL] [Abstract][Full Text] [Related]
22. Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden. Teni FS; Machado A; Murley C; He A; Fink K; Gyllensten H; Glaser A; Alexanderson K; Hillert J; Friberg E Mult Scler Relat Disord; 2023 Jan; 69():104456. PubMed ID: 36529068 [TBL] [Abstract][Full Text] [Related]
23. Real-world treatment preferences among health care providers in the United States in selecting disease modifying therapies for patients with multiple sclerosis: a discrete choice experiment. Bandari D; Adamson M; Bowman M; Gutierrez A; Athavale A; Oak B; Hadker N; Branco F; Geremakis C; Lewin JB; Shankar SL J Med Econ; 2023; 26(1):1507-1518. PubMed ID: 37934412 [TBL] [Abstract][Full Text] [Related]
24. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis. English C; Aloi JJ Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320 [TBL] [Abstract][Full Text] [Related]
25. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
26. Novel therapeutics in multiple sclerosis management: clinical applications. Leist T; Hunter SF; Kantor D; Markowitz C Am J Med; 2014 Jan; 127(1):S2. PubMed ID: 24384114 [TBL] [Abstract][Full Text] [Related]
28. Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis. McGinley M; Rossman IT Neurotherapeutics; 2017 Oct; 14(4):985-998. PubMed ID: 28895071 [TBL] [Abstract][Full Text] [Related]
29. The Multiple Sclerosis Treatment Optimization Program. Langer-Gould A; Cheng SC; Li BH; Kanter MH Ann Clin Transl Neurol; 2021 Nov; 8(11):2146-2154. PubMed ID: 34662494 [TBL] [Abstract][Full Text] [Related]
31. How patients with multiple sclerosis acquire disability. Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840 [TBL] [Abstract][Full Text] [Related]
32. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States. Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738 [TBL] [Abstract][Full Text] [Related]
33. Brain volume loss in multiple sclerosis is independent of disease activity and might be prevented by early disease-modifying therapy. Slezáková D; Kadlic P; Jezberová M; Boleková V; Valkovič P; Minar M Neurol Neurochir Pol; 2023; 57(3):282-288. PubMed ID: 37144903 [TBL] [Abstract][Full Text] [Related]
34. Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview. De Angelis F; Plantone D; Chataway J CNS Drugs; 2018 Jun; 32(6):499-526. PubMed ID: 29968175 [TBL] [Abstract][Full Text] [Related]
35. Timing of Future Remyelination Therapies and Their Potential to Stop Multiple Sclerosis Progression. Zeydan B; Rodriguez M; Kantarci OH Adv Exp Med Biol; 2017; 958():161-170. PubMed ID: 28093713 [TBL] [Abstract][Full Text] [Related]
36. Should MS be treated by escalation or induction therapy? Lazibat I; Nevajda B; Grahovac G; Brinar VV Coll Antropol; 2014 Mar; 38(1):385-93. PubMed ID: 24851647 [TBL] [Abstract][Full Text] [Related]
38. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. He A; Merkel B; Brown JWL; Zhovits Ryerson L; Kister I; Malpas CB; Sharmin S; Horakova D; Kubala Havrdova E; Spelman T; Izquierdo G; Eichau S; Trojano M; Lugaresi A; Hupperts R; Sola P; Ferraro D; Lycke J; Grand'Maison F; Prat A; Girard M; Duquette P; Larochelle C; Svenningsson A; Petersen T; Grammond P; Granella F; Van Pesch V; Bergamaschi R; McGuigan C; Coles A; Hillert J; Piehl F; Butzkueven H; Kalincik T; Lancet Neurol; 2020 Apr; 19(4):307-316. PubMed ID: 32199096 [TBL] [Abstract][Full Text] [Related]
39. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis. Sørensen PS J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763 [TBL] [Abstract][Full Text] [Related]
40. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]